Clinical trial
Phase IV Study of the Effectiveness of Aripiprazole, Quetiapine, and Ziprasidone in the Treatment of First Episode of Non-affective Psychosis Individuals Included in the First Episode Psychosis Clinical Program II (PAFIP II)
NCT02305823 is registered in ClinicalTrials.gov with Fundación Marques de Valdecilla as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase IV Study of the Effectiveness of Aripiprazole, Quetiapine, and Ziprasidone in the Treatment of First Episode of Non-affective Psychosis Individuals Included in the First Episode Psychosis Clinical Program II (PAFIP II)
- Lead sponsor
- Fundación Marques de Valdecilla
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- October 31, 2005
- Completion date
- May 31, 2014
- Enrollment
- 203 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.